THE ROLE OF THE TARGETED THERAPY IN THE TREATMENTOF MALIGNANT MELANOMA

Abstract

Malignant melanoma is a malignant neoplasm of melanocytes and is the deadliest form of skin cancer.Over the past decades, progress in understanding the internal mechanisms of its occurrence and the subsequent discovery of new therapeutic opportunities have revolutionized the treatment of this disease. For patients with locally advanced or metastatic melanoma who have BRAF V600 activating mutations, combined therapy with BRAF and MEK inhibitors is now standard of care. The combination of Encorafenib + Binimetinib, a potent selective MEK1/2 inhibitor, was approved by the FDA for inoperable or metastatic melanoma with BRAF V600E or V600K mutations based on data from the phase III COLUMBUS study (NCT01909453). This article will discuss some of the treatment options for advanced, metastatic malignant melanoma.